Skip to content

Compare

Qsymia vs Xenical

Quick read · 5 min

Last reviewed: September 2026Based on 2 clinical trialsEvery claim linked to source

Qsymia (phentermine / topiramate ER, daily capsule) and Xenical (orlistat, capsule, three times daily with meals) are both approved for weight loss in the United States. No head-to-head trial has compared these two drugs. The figures below come from separate trials, each with its own participants, length and comparison group.

At a glance

Qsymia and Xenical compared on form, trial results, cost and reported side effects
 QsymiaXenical
FormDaily capsule3x daily with meals
How oftenDaily oral capsule — no injectionThree capsules daily, taken with each fat-containing meal
Weight loss in trialsUp to 9.8% — CONQUER (56 weeks)Up to 8.5% — Sjostrom 1-year RCT (52 weeks)
FDA approved20121999
Made byVivusRoche (Xenical) / GSK (Alli OTC)
How it worksPhentermine suppresses appetite by triggering the release of adrenaline-like chemicals in the brain's hunger control centre.Blocks pancreatic lipase enzymes in the small intestine, preventing approximately 30% of dietary fat from being broken down and absorbed.
Monthly cost, self-pay$30–$400/mogeneric; brand runs to $400$40–$400/moover-the-counter strength; prescription runs to $400
Most reported reactionDry mouth 21% (CONQUER)Oily/fatty stools (steatorrhoea) 27% (XENDOS)

Every figure in this table is read from the same trial and label records used everywhere else on this site.

Weight loss in each drug's main trial

No head-to-head trial has compared these two drugs.

Qsymia(phentermine / topiramate ER)9.8%

CONQUER (56 weeks)

Xenical(orlistat)8.5%

Sjostrom 1-year RCT (52 weeks)

In clinical trials, participants taking phentermine / topiramate ER lost on average up to 9.8% of their starting body weight, and participants taking orlistat lost on average up to 8.5%. Those numbers come from two different studies: CONQUER enrolled 2,487 adults with obesity and at least 2 weight-related health conditions over 56 weeks against placebo, while Sjostrom 1-year RCT enrolled 743 adults with obesity over 1 year (52 weeks) against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.

Monthly cost, self-pay

The bar spans the range in each drug's price record — lowest listed price to highest.

Qsymia$30–$400/mo

generic; brand runs to $400

~$30–$80/month generic; ~$200–$400/month brand (Qsymia).

Xenical$40–$400/mo

over-the-counter strength; prescription runs to $400

Prescription Xenical ~$200–$400/month; over-the-counter Alli (60mg) ~$40–$60/month.

Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Qsymia: $30–$400/month. Xenical: $40–$400/month. Insurance, dose and pharmacy all change both figures.

Side effects reported in the trials

CONQUER and XENDOS did not report the same reactions, so there is no shared row to line up. Each drug's own reported rates are listed below.

Qsymia
  • Paraesthesia (tingling in hands/feet)20%
  • Dry mouth21%
  • Constipation17%
  • Insomnia10%
  • Dizziness9%
  • Cognitive effects ('brain fog')8%

From CONQUER

Xenical
  • Oily/fatty stools (steatorrhoea)27%
  • Faecal urgency22%
  • Oily spotting on underwear27%
  • Faecal incontinence8%
  • Abdominal pain/discomfort14%

From XENDOS

A rate is the share of trial participants who reported that reaction, not a prediction for any one person.

How they differ in practice

How you take it

  • QsymiaOnce-daily extended-release capsule
  • XenicalOral capsule 120 mg, three times daily with meals (prescription). Also available OTC as Alli at 60 mg.

Dose build-up

  • Qsymia3.75/23 mg → 15/92 mg, titrated over 14 weeks

Where a drug is not listed here, its prescribing information sets out its own dose steps.

How soon it acts

  • QsymiaAppetite suppression typically begins within the first week; significant weight loss by 12–16 weeks
  • XenicalWeight effects begin from the first week (related to calorie malabsorption), but significant loss takes 8–12 weeks

Heart and metabolic findings

  • QsymiaIn CONQUER, significant reductions in blood pressure, waist circumference, triglycerides, and blood glucose were observed.
  • XenicalIn the 4-year XENDOS trial, orlistat reduced progression from prediabetes to type 2 diabetes by 37% compared to placebo plus lifestyle changes.

As stated in each drug’s trial record — not a claim about which drug protects the heart more.

Other findings recorded

  • QsymiaGeneric now available (from 2025) — significantly lower cost than GLP-1 drugs; improved blood pressure and triglycerides in CONQUER trial
  • Xenical37% reduction in progression to type 2 diabetes (XENDOS, 4 years); only approved obesity drug with a 4-year safety dataset

If you stop taking it

  • QsymiaWeight regain after stopping is expected.
  • XenicalWeight is typically regained after stopping.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Next step most people take

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.